Biocon And Zentiva Sign Liraglutide Deal For 30 European Countries
Zentiva Strengthens Positions As Generics Player In Europe
Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.
